Plant ID: NPO4986
Plant Latin Name: Eschscholzia californica
Taxonomy Genus: Eschscholzia
Taxonomy Family: Papaveraceae
NCBI TaxonomyDB:
3467
Plant-of-the-World-Online:
n.a.
Anodyne; Antianxiety; Antidepressant; Antispasmodic; Diaphoretic; Diuretic; Galactofuge; Odontalgic
China
HTR7; HTR5A; HTR2B; DRD1; HTR6; HTR1A; | |
AURKB; AURKA; KDR; | |
F3; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.426E-12 | 1.321E-08 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.426E-12 | 1.321E-08 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
MF | GO:0005488; binding | GO:0051378; serotonin binding | 4.058E-11 | 1.262E-07 | HTR1A, HTR2B, HTR5A, HTR7 |
BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 9.522E-10 | 1.885E-06 | HTR1A, HTR5A, HTR7 |
BP | GO:0008152; metabolic process | GO:0035404; histone-serine phosphorylation | 5.221E-08 | 8.745E-05 | AURKA, AURKB, DRD1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.185E-07 | 5.360E-04 | CYP1A1, CYP1B1, CYP2D6 |
BP | Unclassified; | GO:0042310; vasoconstriction | 8.614E-07 | 8.932E-04 | HTR1A, HTR2B, HTR7 |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.106E-06 | 1.004E-03 | DRD1, HTR1A, HTR2B, HTR7 |
MF | Unclassified; | GO:0004872; receptor activity | 1.544E-06 | 1.246E-03 | DRD1, F3, HTR1A, HTR2B, HTR5A, HTR6, HTR7, KDR |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.325E-06 | 2.194E-03 | CYP1A1, CYP1B1, CYP2D6 |
CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 4.177E-06 | 2.469E-03 | AURKA, AURKB |
MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 6.262E-06 | 3.409E-03 | AURKA, AURKB |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.764E-06 | 4.438E-03 | CYP1A1, CYP2D6 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.256E-05 | 5.944E-03 | DRD1, HTR1A, HTR2B, HTR5A, HTR6, HTR7, KDR |
BP | GO:0009987; cellular process | GO:0019932; second-messenger-mediated signaling | 1.401E-05 | 6.490E-03 | DRD1, HTR2B, HTR5A, KDR |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.876E-05 | 8.336E-03 | CYP1A1, CYP1B1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.477E-11 | 1.477E-09 | HTR6, HTR7, CYP2D6, HTR1A, HTR2B, HTR5A |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.058E-08 | 1.745E-07 | HTR6, HTR7, HTR1A, HTR2B, DRD1, HTR5A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 6.780E-08 | 7.459E-07 | HTR6, HTR7, HTR2B, DRD1, HTR5A |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.300E-05 | 1.072E-04 | CYP2D6, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.578E-04 | 1.650E-03 | HTR6, HTR1A, DRD1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.000E-04 | 1.650E-03 | CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.694E-04 | 2.213E-03 | CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.316E-04 | 2.605E-03 | CYP1A1, CYP1B1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.447E-03 | 4.774E-03 | HTR2B, DRD1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.258E-03 | 4.612E-03 | CYP1A1, CYP1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | AML | NA | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKA; AURKB; KDR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; AURKB; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; F3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
C00-D49: Neoplasms | Cancer | C00-C96 | AURKA; KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |